Ipilimumab and Bevacizumab in Glioblastoma

Clinical Oncology

Volumn 28, Issue 10, 2016, Pages 622-626

  Carter, T ^a   Shaw, H ^b   Cohn Brown, D ^c   Chester, K ^a   Mulholland, P ^b,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Bevacizumab; glioblastoma; high grade glioma; immunotherapy; ipilimumab

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; IPILIMUMAB; LOMUSTINE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; ANUS FISTULA; ARTHRITIS; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; LUNG EMBOLISM; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RASH; SYSTEMIC THERAPY; TREATMENT RESPONSE; YOUNG ADULT; AGED; BRAIN NEOPLASMS; MELANOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975118725     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.04.042     Document Type: Article

References (32)

1. [1] Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 (2005), 987–996.
2. [2] Stupp, R., Hegi, M.E., Mason, W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (2009), 459–466.
3. [3] Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363 (2010), 711–723.
4. [4] Schadendorf, D., Hodi, F.S., Robert, C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol, 56, 2015, 736.
5. [5] Margolin, K., Ernstoff, M.S., Hamid, O., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13 (2012), 459–465.
6. [6] Hodi, F.S., Lawrence, D., Lezcano, C., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2:7 (2014), 632–642.
7. [7] Norden, A., Young, G., Setayesh, K., et al. Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008), 779–787.
8. [8] Gilbert, M.R., Dignam, J.J., Armstrong, T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New Engl J Med 370 (2014), 699–708.
9. [9] Chinot, O.L., Wick, W., Mason, W., et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. New Engl J Med 370 (2014), 709–722.
10. [10] Vacchelli, E., Aranda, F., Obrist, F., et al. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology, 3, 2014, e29030.
11. [11] Wen, P.Y., Macdonald, D.R., Reardon, D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28 (2010), 1963–1972.
12. [12] Hu, J.L., Sharma, P., Yu, J., Black, K.L., Rudnick, J.D., Ipilimumab for recurrent glioblastoma: a single-institution case series. ASCO Annual Meeting Proceedings, 2014 e13010.
13. [13] Schaff, L.R., Lassman, A.B., Goldlust, S.A., et al. Ipilimumab for recurrent glioblastoma (GBM). Neuro-oncology, 16, 2014, v90.
14. [14] Elamin, Y.Y., Rafee, S., Toomey, S., Hennessy, B.T., Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenvironment 8:1 (2014), 1–7.
15. [15] Klein, S., Gokhale, P., Jones, K., et al. Immune checkpoint blockade activates effective anti-tumor immunity in an orthotopic model of glioblastoma (VAC12P.1119). J Immunol, 194, 2015, 213.
16. [16] Reardon, D., Gokhale, P., Ligon, K., et al. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro-oncology, 16, 2014, v116.
17. [17] Fecci, P.E., Ochiai, H., Mitchell, D.A., et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13 (2007), 2158–2167.
18. [18] Vom Berg, J., Vrohlings, M., Haller, S., et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. J Exp Med 210 (2013), 2803–2811.
19. [19] Wainwright, D.A., Chang, A.L., Dey, M., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20 (2014), 5290–5301.
20. [20] Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. New Engl J Med 369 (2013), 122–133.
21. [21] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med 373 (2015), 23–34.
22. [22] Sampson, J., Vlahovic, G., Desjardins, A., et al. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). J Clin Oncol, 32, 2014, TPS2101.
23. [23] Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
24. [24] Brahmer, J.R., Horn, L., Gandhi, L., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Annual Meeting Proceedings, 2014 8112.
25. [25] Motzer, R., Escudier, B., McDermott, D., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015), 1803–1813.
26. [26] Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
27. [27] NICE, Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. National Institute for Health and Care Excellence (NICE) technology appraisal guidance, 2015 TA357. Available at: http://www.nice.org.uk.
28. [28] Pennock, G.K., Chow, L.Q., The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 20 (2015), 812–822.
29. [29] Webster, R.M., The immune checkpoint inhibitors: where are we now?. Nat Rev Drug Disc 13:12 (2014), 883–884.
30. [30] Pilones, K.A., Vanpouille-Box, C., Demaria, S., Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 25 (2015), 28–33.
31. [31] Belcaid, Z., Phallen, J.A., Zeng, J., et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS one, 9(7), 2014, e101764.
32. [32] Okada, H., Weller, M., Huang, R., et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16 (2015), e534–e542.